What is Zacks Research’s Estimate for Neogen Q2 Earnings?

Neogen Co. (NASDAQ:NEOG) – Research analysts at Zacks Research cut their Q2 2025 earnings per share estimates for Neogen in a research report issued to clients and investors on Thursday, January 2nd. Zacks Research analyst R. Department now expects that the company will earn $0.11 per share for the quarter, down from their prior forecast of $0.12. The consensus estimate for Neogen’s current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Neogen’s FY2027 earnings at $0.72 EPS.

Several other brokerages also recently commented on NEOG. Guggenheim started coverage on Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. StockNews.com upgraded Neogen to a “sell” rating in a report on Monday, September 30th.

Neogen Trading Up 2.0 %

NEOG opened at $12.98 on Monday. Neogen has a fifty-two week low of $11.46 and a fifty-two week high of $19.88. The firm has a market capitalization of $2.81 billion, a PE ratio of -118.00 and a beta of 1.23. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.41 and a quick ratio of 2.79. The company’s 50-day moving average is $13.60 and its 200 day moving average is $15.14.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Thursday, October 10th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $217.00 million for the quarter, compared to analyst estimates of $215.05 million. Neogen had a positive return on equity of 2.80% and a negative net margin of 2.58%. The business’s quarterly revenue was down 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 EPS.

Insider Buying and Selling

In related news, CEO John Edward Adent bought 14,500 shares of the company’s stock in a transaction on Friday, October 11th. The shares were purchased at an average cost of $13.80 per share, for a total transaction of $200,100.00. Following the completion of the purchase, the chief executive officer now directly owns 216,477 shares in the company, valued at $2,987,382.60. The trade was a 7.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neogen

Large investors have recently modified their holdings of the stock. Inspire Investing LLC grew its holdings in Neogen by 2.7% during the second quarter. Inspire Investing LLC now owns 26,074 shares of the company’s stock valued at $408,000 after purchasing an additional 685 shares during the period. Stephens Inc. AR grew its stake in shares of Neogen by 2.6% during the 3rd quarter. Stephens Inc. AR now owns 35,930 shares of the company’s stock worth $604,000 after acquiring an additional 909 shares during the period. Arizona State Retirement System increased its holdings in Neogen by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 57,609 shares of the company’s stock worth $900,000 after acquiring an additional 1,079 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Neogen by 142.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock valued at $33,000 after acquiring an additional 1,165 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in Neogen by 3.4% during the second quarter. Commonwealth Equity Services LLC now owns 36,630 shares of the company’s stock valued at $573,000 after purchasing an additional 1,190 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.